Supplement Industry Stained By Criticism Due Irresponsible Firms
This article was originally published in The Rose Sheet
FDA's warnings to industry "about safety have not always been met adequately or even uniformly accepted," says Steve Tave, director of the agency's dietary supplement programs.
You may also be interested in...
A report submitted with appropriations legislation negotiated by conference committee and approved by both chambers instructs FDA to report to Congress about its activities and staffing for oversight of supplement manufacturers and marketers. In an indication members are aware of the scope of FDA's responsibilities in the sector, report also asks agency to provide information on work related to "manufacturers and marketers of products claiming to be dietary supplements."
FDA agrees with public health advocates that ingredients should be on a potential list of those available when Congress passed DSHEA only after current substantiation for a reasonable expectation of safety for their intended uses.
Manufacturers, ingredient suppliers and other parties submitting NDI notifications can improve the industry's outlook by "anticipating future products that haven't been brought to market yet" and proposing the highest concentration of an ingredient for the broadest variety of uses, says ODSP senior advisory Cara Welch.